ORSERDUTM (ELACESTRANT)
Publications
Elacestrant in ER+, HER2– MBC with ESR1-mutated tumors:
Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups
Journal of Clinical Oncology (2022): Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial
Journal of Clinical Oncology (2021): Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Presentations
Nothing found.
ELZONRIS® (TAGRAXOFUSP)
Publications
Journal of Clinical Oncology (2022): Long-Term Benefits of Tagraxofusp for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
New England Journal of Medicine (2019): Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Presentations
SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model
Results From Ongoing Phase 2 Registration Study Of SL-401 In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 2016.
Results From Phase 2 Registration Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Lead-in Completed, Expansion Stage Ongoing. ASCO 2016.
Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). ASH 2015.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo. ASH 2015.
SL-801
Nothing found.
SL-701
Nothing found.